The short version of alpha-MSH analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-23 and is reviewed periodically as new material appears.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Another explanation is that the word hoagie arose in the late 19th to early 20th centuries, among the Italian community in South Philadelphia; at the time "on the hoke" meant that someone was destitute. Deli owners gave away scraps of cheeses and meats in an Italian bread-roll known as a "hokie", but Italian immigrants pronounced it "hoagie". Yet another possible origin of the term, as conveyed by Sociology professor Howard Robboy, is that a man in Philadelphia, Alphonso DePalma, who later opened a sandwich shop there, claimed to have said in 1928, "You have to be a hog to eat one of those." DePalma styled himself as "King of the Hoggies" (and eventually "Hoagies") and at one time had several "hoggie" shops around the city. Shortly after World War II, there were numerous varieties of the term in use throughout Philadelphia. By the 1940s, the spelling "hoagie" dominated less-used variations like "hoogie" and "hoggie". By 1955, restaurants throughout the area were using the term hoagie. Listings in Pittsburgh show hoagies arriving in 1961 and becoming widespread in that city by 1966. Former Philadelphia mayor (and later Pennsylvania governor) Ed Rendell declared the hoagie to be the "Official Sandwich of Philadelphia". However, there are claims that the hoagie was actually a product of nearby Chester, Pennsylvania. DiCostanza's in Boothwyn, Pennsylvania claims that the mother of DiConstanza's owner originated the hoagie in 1925 in Chester.
Bone grafting is a type of transplantation used to replace missing bone tissue or stimulate the healing of fractures. This surgical procedure is useful for repairing bone fractures that are extremely complex, pose a significant health risk to the patient, or fail to heal properly, leading to pseudoarthrosis. While some small or acute fractures can heal without bone grafting, the risk is greater for large fractures, such as compound fractures. Additionally, structural or morcellized bone grafting can be used in joint replacement revision surgery when wide osteolysis is present. Bone generally has the ability to regenerate completely but requires a very small fracture space or some sort of scaffold to do so. Bone grafts may be autologous (bone harvested from the patient's own body, often from the iliac crest), allograft (cadaveric bone usually obtained from a bone bank), or synthetic (often made of hydroxyapatite or other naturally occurring and biocompatible substances) with similar mechanical properties to bone. Most bone grafts are expected to be resorbed and replaced as the natural bone heals over a few months' time. The principles involved in successful bone grafts include osteoconduction (guiding the reparative growth of the natural bone), osteoinduction (encouraging undifferentiated cells to become active osteoblasts), and osteogenesis (living bone cells in the graft material contribute to bone remodeling). Osteogenesis only occurs with autograft tissue and allograft cellular bone matrices.
Newsom's first political experience came when he volunteered for Willie Brown's successful campaign for mayor in 1995. Newsom hosted a private fundraiser at his PlumpJack Café. Brown appointed Newsom to a vacant seat on the Parking and Traffic Commission in 1996, and he was later elected president of the commission. Brown appointed him to the San Francisco Board of Supervisors seat vacated by Kevin Shelley in 1997. At the time, he was the youngest member of San Francisco's board of supervisors. Newsom was sworn in by his father and pledged to bring his business experience to the board. Brown called Newsom "part of the future generation of leaders of this great city". Newsom described himself as a "social liberal and a fiscal watchdog". He was elected to a full four-year term to the board in 1998. San Francisco voters chose to abandon at-large elections to the board for the previous district system in 1999. Newsom was reelected in 2000 and 2002 to represent the second district, which includes Pacific Heights, the Marina, Cow Hollow, Sea Cliff, and Laurel Heights, which had San Francisco's highest income level and highest Republican registration. Newsom paid $500 to the San Francisco Republican Party to appear on the party's endorsement slate in 2000 while running for Supervisor. He was reelected. As a San Francisco Supervisor, Newsom gained public attention for his role in advocating reform of the city's municipal railway (Muni). He was one of two supervisors endorsed by Rescue Muni, a transit riders group, in his 1998 reelection.
Sources: en.wikipedia.org
Lately Executive Director, City Building. For services to Equality and Inclusion in Construction. Dr. Shriti Pattani. Lately President, The Society of Occupational Medicine. For services to Occupational Health. Nicola Heather Anne Patterson. Lately Director of Nursing, South Eastern Health and Social Care Trust. For services to Health and Social Care in Northern Ireland. Professor Rupert Mark Pearse. Professor of Intensive Care Medicine, Queen Mary University of London. For services to Intensive Care Medicine. Amy Sarah Perrin. Founder, The Marmalade Trust. For services to Older People. Oscar Victor Pinto-Hervia. Founder, Hervia. For services to Fashion and to Charity. Dr. Madsen Pirie. President, Adam Smith Institute. For services to Public Policy. Mary Margaret Portas. Retail Consultant and Broadcaster. For services to Business, to Broadcasting and to Charity. Alexander Reedijk. General Director, Scottish Opera. For services to the Performing Arts in Scotland. Marvin Rees. Mayor, Bristol City Council. For services to Local Government. Professor Julian Daryl Richards. Professor of Archaeology, University of York. For services to Heritage and Digital Archiving. Julian Richmond-Watson. Chair, Thoroughbred Breeders Association. For services to the British Horseracing Industry. José Salvador Riera. Deputy Director, Communications, Department for Culture, Media and Sport. For Public Service. Martin John Rigley, MBE. Lately Managing Director, Lindhurst Engineering Ltd. For services to the East Midlands Covid-19 Response and to the community in Derbyshire and Nottinghamshire.
== Accrediting organizations == For CLIA laboratories licensed under a Certificate of Accreditation (CoA), bi-annual inspections are conducted by a third-party accreditation organization (AO) that meets or exceeds the CLIA requirements. Though the Foundation for the Accreditation of Cellular Therapy (FACT) (formerly the Foundation for Accreditation of Hematopoietic Cell Transplantation) does not have deeming status under CLIA, most laboratories involved in cell therapies are accredited by FACT. In Dec 2022, TJC announced it would no longer recognize the Commission on Office Laboratory Accreditation (COLA) for lab accreditation at TJC hospitals, effective Jan 1, 2023, and facilities would have until Dec 31, 2024, to transition their accreditation. With the COVID-driven inspection backlog and a lack of inspectors, the move was criticized as being purely a financially driven attempt to capture additional market share. No reason for the change was given by CLIA, COLA, or TJC. TJC began recognizing COLA accreditation in 1997.
== External links == WHO fact sheet on opioid overdose Community management of opioid overdose (PDF). World Health Organization. 2014. ISBN 978-92-4-154881-6. Archived from the original (PDF) on 1 September 2022.
== History == The FDA approved cipaglucosidase alfa in combination with miglustat based on evidence from a clinical trial (Trial 1/NCT03729362) of 123 participants with late-onset Pompe disease. Safety data from the use of cipaglucosidase alfa in combination with miglustat was primarily obtained from one clinical trial (Trial 1, NCT03729362). Data from two other trials (Trial 2/NCT02675465 and Trial 3/NCT04138277) were also reviewed for completeness of the safety assessment. The three trials enrolled 151 participants with late-onset Pompe disease. The trials were conducted at 61 sites in 24 countries around the world, including the United States. In Trial 1, 123 adults with late-onset Pompe disease received either cipaglucosidase alfa intravenously once every two weeks for 52 weeks in combination with miglustat, or another medication (called the active comparator) intravenously once every two weeks for 52 weeks in combination with placebo. Of the 123 participants, 95 previously received enzyme replacement therapy, and 28 never received enzyme replacement therapy before the trial. Neither the participants nor the healthcare providers knew which treatment was being given until after Week 52.
Sources: en.wikipedia.org
==== Closed-loop recycling ==== There are several other harmful environmental impact from synthetic textile production, including large amount of greenhouse gas emissions, high energy consumption and landfill waste. A typical textile mill consumes approximately 1.6 million liters of water to produce 8,000 kilograms of fabric. This is a worldwide problem since the textile industry contributes to about 10 percent of global greenhouse gas emissions. During 2016 alone, only 1 percent of the 180,000 tons of textile waste produced was recycled into new clothes. The remaining old textile fibers ended up in a landfill as waste. One solution that is currently being implemented within the textile industry to combat these issues is a closed loop recycling system. In the context of the textile industry, closed loop recycling involves collecting used textiles, processing them through various mechanical, chemical or biological recycling methods to turn used, worn down textiles into new textiles. Within a closed loop recycling system, textiles can either be recycled into a similar product, upcycled into a new, higher quality product, or downcycled into a new, lower quality product. This approach reduces waste, conserves resources, and minimizes the environmental impact of textile production by promoting a circular economy where materials are recycled and reused in a continuous, closed loop.
The pellagra epidemic in the American south had subsided in periods of low cotton production (late 1910s to early 1920s, the Great Depression), but it had consistently rebounded as cotton production recovered. The cause would not be understood until 1937, when the relation with niacin was discovered. Voluntary food fortification and periods of mandatory fortification on the state and federal levels soon followed, coinciding with a continuous drop in pellagra deaths. By the 1950s, the disease was virtually eliminated from the US.
A chaotropic agent is a molecule in water solution that can disrupt the hydrogen bonding network between water molecules (i.e. exerts chaotropic activity). This has an effect on the stability of the native state of other molecules in the solution, mainly macromolecules (proteins, nucleic acids) by weakening the hydrophobic effect. For example, a chaotropic agent reduces the amount of order in the structure of a protein formed by water molecules, both in the bulk and the hydration shells around hydrophobic amino acids, and may cause its denaturation. Conversely, an antichaotropic agent (kosmotropic) is a molecule in an aqueous solution that will increase the hydrophobic effects within the solution. Antichaotropic salts such as ammonium sulphate can be used to precipitate substances from the impure mixture. This is used in protein purification processes, to remove undesired proteins from solution.
Electrical stimulation using implantable devices came into modern usage in the 1980s, and its techniques and applications have continued to develop and expand. These are methods where an operation is required to position an electrode. The stimulator, with the battery, similar to a pacemaker, may also be implanted, or may remain outside the body. In general, neuromodulation systems deliver electrical currents and typically consist of the following components: An epidural, subdural, or parenchymal electrode placed via minimally invasive needle techniques (so-called percutaneous leads) or an open surgical exposure to the target (surgical "paddle" or "grid" electrodes), or stereotactic implants for the central nervous system, and an implanted pulse generator (IPG). Depending on the distance from the electrode access point, an extension cable may also be added into the system. The IPG can have either a non-rechargeable battery needing replacement every 2–5 years (depending on stimulation parameters) or a rechargeable battery that is replenished via an external inductive charging system. Although most systems operate via delivery of a constant train of stimulation, there has recently been an emergence of so-called "feed-forward" stimulation, in which the device's activation is contingent on a physiological event, such as an epileptic seizure. In this circumstance, the device is activated and delivers a desynchronizing pulse to the cortical area that is undergoing an epileptic seizure.
Specialized scalp tattoos can also mimic the appearance of a short buzzed haircut. Androgenic alopecia also occurs in women, and more often presents as diffuse thinning without hairline recession. Like its male counterpart, the condition rarely leads to total hair loss. Treatment options are similar to those for men, although topical or systemic estrogen is used more often.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.